• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ALKBH5 通过 mA 依赖性表观遗传沉默 pre-miR-181b-1/YAP 信号轴抑制骨肉瘤的肿瘤进展。

ALKBH5 suppresses tumor progression via an mA-dependent epigenetic silencing of pre-miR-181b-1/YAP signaling axis in osteosarcoma.

机构信息

Department of Orthopedics at The First Affiliated Hospital, and Department of Pharmacology at College of Pharmacy (The Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), Harbin Medical University, 150086, Harbin, China.

Department of Pharmacy, The Second Affiliated Hospital of Harbin Medical University, 150086, Harbin, China.

出版信息

Cell Death Dis. 2021 Jan 11;12(1):60. doi: 10.1038/s41419-020-03315-x.

DOI:10.1038/s41419-020-03315-x
PMID:33431791
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7801648/
Abstract

ALKBH5 is the main enzyme for mA-based demethylation of RNAs and it has been implicated in many biological and pathophysiological processes. Here, we aimed to explore the potential involvement of ALKBH5 in osteosarcoma and decipher the underlying cellular/molecular mechanisms. We discovered downregulated levels of demethylase ALKBH5 were correlated with increased mA methylation in osteosarcoma cells/tissues compared with normal osteoblasts cells/tissues. ALKBH5 overexpression significantly suppressed osteosarcoma cell growth, migration, invasion, and trigged cell apoptosis. In contrast, inhibition of ALKBH5 produced the opposite effects. Whereas ALKBH5 silence enhanced mA methylations of pre-miR-181b-1 and YAP-mRNA exerting oncogenic functions in osteosarcoma. Moreover, upregulation of YAP or downregulation of mature miR-181b-5p displayed a remarkable attenuation of anti-tumor activities caused by ALKBH5. Further results revealed that mA methylated pre-miR-181b-1 was subsequently recognized by mA-binding protein YTHDF2 to mediate RNA degradation. However, methylated YAP transcripts were recognized by YTHDF1 to promote its translation. Therefore, ALKBH5-based mA demethylation suppressed osteosarcoma cancer progression through mA-based direct/indirect regulation of YAP. Thus, ALKBH5 overexpression might be considered a new approach of replacement therapy for osteosarcoma treatment.

摘要

ALKBH5 是 mA 基 RNA 去甲基化的主要酶，它与许多生物学和病理生理学过程有关。在这里，我们旨在探讨 ALKBH5 在骨肉瘤中的潜在作用，并阐明其潜在的细胞/分子机制。我们发现与正常成骨细胞/组织相比，骨肉瘤细胞/组织中去甲基酶 ALKBH5 的下调水平与 mA 甲基化的增加相关。ALKBH5 的过表达显著抑制骨肉瘤细胞的生长、迁移、侵袭和触发细胞凋亡。相反，ALKBH5 的抑制产生了相反的效果。而 ALKBH5 的沉默增强了 pre-miR-181b-1 的 mA 甲基化和 YAP-mRNA 的致癌功能，在骨肉瘤中发挥致癌作用。此外，YAP 的上调或成熟 miR-181b-5p 的下调显示出对 ALKBH5 引起的抗肿瘤活性的显著衰减。进一步的结果表明，mA 甲基化的 pre-miR-181b-1 随后被 mA 结合蛋白 YTHDF2 识别，以介导 RNA 降解。然而，甲基化的 YAP 转录本被 YTHDF1 识别，以促进其翻译。因此，基于 ALKBH5 的 mA 去甲基化通过 mA 对 YAP 的直接/间接调控抑制骨肉瘤的癌症进展。因此，ALKBH5 的过表达可能被认为是骨肉瘤治疗的一种新的替代治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6464/7801648/3f170d644321/41419_2020_3315_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6464/7801648/eff1c49c28de/41419_2020_3315_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6464/7801648/1f90971bd4dd/41419_2020_3315_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6464/7801648/2192da58f03d/41419_2020_3315_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6464/7801648/b2fef35a6538/41419_2020_3315_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6464/7801648/448d74f8cc7b/41419_2020_3315_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6464/7801648/75a7ffe48fac/41419_2020_3315_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6464/7801648/1ef69972ed74/41419_2020_3315_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6464/7801648/3f170d644321/41419_2020_3315_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6464/7801648/eff1c49c28de/41419_2020_3315_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6464/7801648/1f90971bd4dd/41419_2020_3315_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6464/7801648/2192da58f03d/41419_2020_3315_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6464/7801648/b2fef35a6538/41419_2020_3315_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6464/7801648/448d74f8cc7b/41419_2020_3315_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6464/7801648/75a7ffe48fac/41419_2020_3315_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6464/7801648/1ef69972ed74/41419_2020_3315_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6464/7801648/3f170d644321/41419_2020_3315_Fig8_HTML.jpg

相似文献

1
ALKBH5 suppresses tumor progression via an mA-dependent epigenetic silencing of pre-miR-181b-1/YAP signaling axis in osteosarcoma.ALKBH5 通过 mA 依赖性表观遗传沉默 pre-miR-181b-1/YAP 信号轴抑制骨肉瘤的肿瘤进展。
Cell Death Dis. 2021 Jan 11;12(1):60. doi: 10.1038/s41419-020-03315-x.
2
mA demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC.mA 去甲基化酶 ALKBH5 通过降低 YTHDF 介导的 YAP 表达以及抑制 miR-107/LATS2 介导的 YAP 活性来抑制非小细胞肺癌的肿瘤生长和转移。
Mol Cancer. 2020 Feb 27;19(1):40. doi: 10.1186/s12943-020-01161-1.
3
ALKBH5 suppresses malignancy of hepatocellular carcinoma via mA-guided epigenetic inhibition of LYPD1.ALKBH5 通过 mA 引导的 LYPD1 表观遗传抑制抑制肝癌的恶性程度。
Mol Cancer. 2020 Aug 10;19(1):123. doi: 10.1186/s12943-020-01239-w.
4
ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner.ALKBH5 通过 m6A-YTHDF2 依赖的方式调节 STAT3 活性，影响骨肉瘤的增殖和致瘤性。
EBioMedicine. 2022 Jun;80:104019. doi: 10.1016/j.ebiom.2022.104019. Epub 2022 Apr 28.
5
ALKBH5 facilitates the progression of infantile hemangioma by increasing FOXF1 expression in a mA-YTHDF2 dependent manner to activate HK-2 signaling.ALKBH5 通过增加 FOXF1 表达以 mA-YTHDF2 依赖的方式促进婴儿血管瘤的进展，从而激活 HK-2 信号通路。
Mol Cell Biochem. 2024 Nov;479(11):3153-3166. doi: 10.1007/s11010-024-04936-y. Epub 2024 Feb 2.
6
RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.RNA 去甲基酶 ALKBH5 通过 m6A-YTHDF2 依赖的方式在后转录水平激活 PER1 来阻止胰腺癌细胞的进展。
Mol Cancer. 2020 May 19;19(1):91. doi: 10.1186/s12943-020-01158-w.
7
mA demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling.mA 去甲基化酶 ALKBH5 通过降低 WIF-1 RNA 甲基化并介导 Wnt 信号通路抑制胰腺癌发生。
Mol Cancer. 2020 Jan 6;19(1):3. doi: 10.1186/s12943-019-1128-6.
8
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential.RNA 去甲基酶 ALKBH5 在癌症中的作用：从机制到治疗潜力。
J Hematol Oncol. 2022 Jan 21;15(1):8. doi: 10.1186/s13045-022-01224-4.
9
ALKBH5 regulates cardiomyocyte proliferation and heart regeneration by demethylating the mRNA of YTHDF1.ALKBH5 通过去甲基化 YTHDF1 的 mRNA 来调节心肌细胞增殖和心脏再生。
Theranostics. 2021 Jan 1;11(6):3000-3016. doi: 10.7150/thno.47354. eCollection 2021.
10
LINC00659 cooperated with ALKBH5 to accelerate gastric cancer progression by stabilising JAK1 mRNA in an m A-YTHDF2-dependent manner.LINC00659 通过与 ALKBH5 合作，以 m A-YTHDF2 依赖的方式稳定 JAK1 mRNA，从而加速胃癌的进展。
Clin Transl Med. 2023 Mar;13(3):e1205. doi: 10.1002/ctm2.1205.

引用本文的文献

1
Mechanistic insights into the role of RNA demethylase ALKBH5 in malignant tumor therapy.RNA去甲基化酶ALKBH5在恶性肿瘤治疗中作用的机制性见解
J Transl Med. 2025 Aug 13;23(1):905. doi: 10.1186/s12967-025-06938-w.
2
MARCH8/NSUN6/ROS-mediated DNA damage positive feedback loop regulates cisplatin resistance in osteosarcoma.MARCH8/NSUN6/活性氧介导的DNA损伤正反馈回路调节骨肉瘤中的顺铂耐药性。
Cell Death Differ. 2025 Jul 19. doi: 10.1038/s41418-025-01544-1.
3
Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.

本文引用的文献

1
mA Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer.mA 修饰在编码和非编码 RNA 中的作用及其在癌症中的治疗意义。
Cancer Cell. 2020 Mar 16;37(3):270-288. doi: 10.1016/j.ccell.2020.02.004.
2
MK5 Regulates YAP Stability and Is a Molecular Target in YAP-Driven Cancers.MK5 调节 YAP 的稳定性，是 YAP 驱动型癌症的分子靶标。
Cancer Res. 2019 Dec 15;79(24):6139-6152. doi: 10.1158/0008-5472.CAN-19-1339. Epub 2019 Oct 2.
3
The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1.
将表观遗传调节因子作为克服癌症治疗耐药性的一条有前景的途径。
Signal Transduct Target Ther. 2025 Jul 18;10(1):219. doi: 10.1038/s41392-025-02266-z.
4
Reciprocal regulation between m6 A modifications and non-coding RNAs: emerging roles in cancer therapeutic resistance.m6A修饰与非编码RNA之间的相互调控：在癌症治疗耐药性中的新作用
Discov Oncol. 2025 May 25;16(1):920. doi: 10.1007/s12672-025-02641-w.
5
From bone marrow mesenchymal stem cells to diseases: the crucial role of mA methylation in orthopedics.从骨髓间充质干细胞到疾病：甲基化在骨科中的关键作用
Stem Cell Res Ther. 2025 May 6;16(1):228. doi: 10.1186/s13287-025-04364-9.
6
ALKBH5 Inhibits YTHDF2-m6A-Mediated Degradation of RCN1 mRNA to Promote Keloid Formation by Activating IRE1α-XBP1-Mediated ER Stress.ALKBH5通过激活IRE1α-XBP1介导的内质网应激抑制YTHDF2-m6A介导的RCN1 mRNA降解，从而促进瘢痕疙瘩形成。
J Cosmet Dermatol. 2025 Apr;24(4):e70177. doi: 10.1111/jocd.70177.
7
Regulation of Skeletogenic Pathways by m6A RNA Modification: A Comprehensive Review.m6A RNA修饰对成骨途径的调控：综述
Calcif Tissue Int. 2025 Apr 3;116(1):58. doi: 10.1007/s00223-025-01367-9.
8
M6A Demethylase ALKBH5 in Human Diseases: From Structure to Mechanisms.人类疾病中的m6A去甲基化酶ALKBH5：从结构到机制
Biomolecules. 2025 Jan 21;15(2):157. doi: 10.3390/biom15020157.
9
N-Methyladenosine modification mediated by METTL3 promotes DNA-PKcs expression to induce anlotinib resistance in osteosarcoma.由METTL3介导的N-甲基腺苷修饰促进DNA-PKcs表达，从而诱导骨肉瘤对安罗替尼产生耐药性。
Clin Transl Med. 2025 Feb;15(2):e70228. doi: 10.1002/ctm2.70228.
10
Research progress on N6-methyladenosine RNA modification in osteosarcoma: functions, mechanisms, and potential clinical applications.骨肉瘤中N6-甲基腺苷RNA修饰的研究进展：功能、机制及潜在临床应用
Med Oncol. 2025 Jan 24;42(3):55. doi: 10.1007/s12032-024-02597-x.
m6A 甲基转移酶 METTL3 通过调控 LEF1 的 m6A 水平促进骨肉瘤的进展。
Biochem Biophys Res Commun. 2019 Aug 27;516(3):719-725. doi: 10.1016/j.bbrc.2019.06.128. Epub 2019 Jun 26.
4
mA mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade.mA mRNA 去甲基酶 FTO 调控黑色素瘤的肿瘤发生和对抗 PD-1 封锁的反应。
Nat Commun. 2019 Jun 25;10(1):2782. doi: 10.1038/s41467-019-10669-0.
5
YTHDF1 Regulates Tumorigenicity and Cancer Stem Cell-Like Activity in Human Colorectal Carcinoma.YTHDF1调节人类结直肠癌的致瘤性和癌症干细胞样活性。
Front Oncol. 2019 May 3;9:332. doi: 10.3389/fonc.2019.00332. eCollection 2019.
6
RNA mA methylation regulates the epithelial mesenchymal transition of cancer cells and translation of Snail.RNA mA 甲基化调控癌细胞的上皮间质转化和 Snail 的翻译。
Nat Commun. 2019 May 6;10(1):2065. doi: 10.1038/s41467-019-09865-9.
7
YAP Aggravates Inflammatory Bowel Disease by Regulating M1/M2 Macrophage Polarization and Gut Microbial Homeostasis.YAP 通过调节 M1/M2 巨噬细胞极化和肠道微生物稳态加重炎症性肠病。
Cell Rep. 2019 Apr 23;27(4):1176-1189.e5. doi: 10.1016/j.celrep.2019.03.028.
8
YAP-independent mechanotransduction drives breast cancer progression.YAP 非依赖性机械转导驱动乳腺癌进展。
Nat Commun. 2019 Apr 23;10(1):1848. doi: 10.1038/s41467-019-09755-0.
9
Circular RNA circTADA2A promotes osteosarcoma progression and metastasis by sponging miR-203a-3p and regulating CREB3 expression.环状 RNA circTADA2A 通过海绵吸附 miR-203a-3p 和调控 CREB3 表达促进骨肉瘤的进展和转移。
Mol Cancer. 2019 Apr 2;18(1):73. doi: 10.1186/s12943-019-1007-1.
10
RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.RNA N6-甲基腺嘌呤去甲基化酶 FTO 通过抑制 BNIP3 促进乳腺癌进展。
Mol Cancer. 2019 Mar 28;18(1):46. doi: 10.1186/s12943-019-1004-4.